Make that 2 prospective blockbuster approvals in 1 day for Novartis as FDA OKs targeted cancer therapy
May 24 is going to go down as a big day in Novartis’ 2019 highlight reel.
Not only did the FDA stamp an OK …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
